Source: FinanzNachrichten

Macopharma SA: PL BioScience GmbH: PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.

The companies agree to a worldwide Human Platelet Lysate (HPL) Patent License and Assignment Agreement, including redirection of HPL customers from Macopharma to PL BioScience. PL BioScience GmbH,...

Read full article »
Est. Annual Revenue
$500M-1.0B
Est. Employees
1.0-5.0K
Ronald De Lagrange's photo - President & CEO of Macopharma SA

President & CEO

Ronald De Lagrange

CEO Approval Rating

75/100

Read more